Skip to content
OpenCapital
Get started

Avanos Medical AVNS PM&R — Research and development expenses

Similar metrics at other companies

Becton, Dickinson and Company logo
BDXMedical — Research and development expense
$130.75M+17.0%
Adaptive Biotechnologies logo
ADPTMrd Business — Research And Development Expense
$9.23M+0.7%
Enovis logo
ENOVPrevention & Recovery — Research and development expense
$7.75M-16.2%
Baxter International logo
BAXMedical Products & Therapies — Research and development expenses
$54M-8.5%
Chemours logo
CCAdvanced Performance Materials — Research And Development Expense
$11M-8.3%
TFX
TFXEMEA — Research and development expenses
$24.5M+257%

Other financials

Income statement

See full
Revenue$182.2M+8.8%
Gross profit$94.2M+4.9%
Operating income$8.9M-13.6%
Net income$5.1M-22.7%
EPS (diluted)$0.11-21.4%

Balance sheet

See full
Cash & equivalents$65.6M-32.4%
Total debt$138.4M-1.8%
Total equity$782.1M-6.8%
Total assets$1.1B-5.2%

Cash flow

See full
Operating cash flow-$12.3M-148%
CapEx$4.3M-35.8%
Free cash flow-$16.6M-187%

Valuation

See full
Market cap$1.17B+108%
Enterprise value$1.24B+105%
P/S1.6×+0.8×

Profitability

See full
Gross margin50%-4.6pp
Operating margin-9.1%-4.2pp
Net margin-10.4%-4.7pp
FCF margin1.6%-14.9pp

Returns & leverage

See full
Return on equity-9.2%-3.9pp
Debt / equity0.2×0.0×
Current ratio2.5×-0.1×

Where this comes from

Reported directly by Avanos Medical in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Avanos Medical’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avanos Medical's pm&r — research and development expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avanos Medical's PM&R — research and development expenses?
Avanos Medical (AVNS) reported PM&R — research and development expenses of -$1.3M in Q1 2026.
How has Avanos Medical's PM&R — research and development expenses changed year-over-year?
Avanos Medical's PM&R — research and development expenses decreased by 18.2% year-over-year, from -$1.1M to -$1.3M.
What is the long-term trend for Avanos Medical's PM&R — research and development expenses?
Over 2 years (2023 to 2025), Avanos Medical's PM&R — research and development expenses has grown at a -30.0% compound annual growth rate (CAGR), from -$9.8M to -$4.8M.
What does PM&R — research and development expenses mean?
Reflects the investment in innovation, clinical trials, and product development specifically allocated to the Pain Management and Recovery segment. These expenditures are critical for maintaining a competitive pipeline and ensuring long-term technological relevance in the medical device market.